CHD/Prevention

Top Story

Bempedoic acid may further reduce LDL when added to high-intensity statin therapy

May 22, 2017

PHILADELPHIA — Patients treated with bempedoic acid in addition to high-intensity statin therapy had a reduction in LDL, according to results presented in a late-breaker session at the National Lipid Association Scientific Sessions.

“Bempedoic acid, or ETC-1002, is a pro-drug, and it needs to be converted into its active form by a very specific Acyl-CoA synthetase that is ... found in the liver and to a much lesser extent in the kidneys, but certainly not in the muscle cell,” Mary McGowan, MD, chief medical officer at Esperion Therapeutics and director of the Lipid Clinic at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, said in the presentation. “By [converting] ETC-1002, you get ETC-1002 CoA, and this is an inhibitor of ATP citrate lyase. ATP citrate lyase is an enzyme upstream from the HMG-CoA reductase enzyme, and as such, inhibition here does exactly what statins do.”

Meeting News

Experts highlight important literature in lipidology

May 22, 2017
PHILADELPHIA — Nutrition, gene variants and familial hypercholesterolemia were the topics of three important journal articles discussed at the National Lipid…
In the Journals

Statins yielded no benefit for primary cardiovascular prevention in older adults

May 22, 2017
Among patients aged 65 years and older, there was no difference in all-cause mortality or cardiovascular outcomes between pravastatin and usual care for primary…
Meeting NewsVideo

VIDEO: New NLA president discusses updates to PCSK9 inhibitor recommendations

May 22, 2017
PHILADELPHIA — In this Cardiology Today video exclusive, James A. Underberg, MD, MS, FACPM, FACP, FNLA, new president of the National Lipid Association, discusses…
Trial Scorecards

Trial Scorecard: PRECISION

Cardiology Today, December 2016
Patients with osteoarthritis or rheumatoid arthritis were assigned celecoxib, ibuprofen or naproxen and assessed for CV…
More »
Video
Meeting News

VIDEO: Genes play a major role in weight gain

November 2, 2016
More »
Featured
American College of Cardiology Annual Scientific Session

American College of Cardiology Annual Scientific Session

Video
Meeting News

VIDEO: Weight-loss medications can help patients deal with appetite

November 3, 2016
More »
Meeting News

Bempedoic acid may further reduce LDL when added to high-intensity statin therapy

May 22, 2017
PHILADELPHIA — Patients treated with bempedoic acid in addition to high-intensity statin therapy had a reduction in LDL, according to results…

Meeting News

Experts highlight important literature in lipidology

May 22, 2017
PHILADELPHIA — Nutrition, gene variants and familial hypercholesterolemia were the topics of three important journal articles discussed at the…

In the Journals

Statins yielded no benefit for primary cardiovascular prevention in older adults

May 22, 2017
Among patients aged 65 years and older, there was no difference in all-cause mortality or cardiovascular outcomes between pravastatin and usual care…

Meeting NewsVideo

VIDEO: New NLA president discusses updates to PCSK9 inhibitor recommendations

May 22, 2017
PHILADELPHIA — In this Cardiology Today video exclusive, James A. Underberg, MD, MS, FACPM, FACP, FNLA, new president of the National Lipid…

ARCH study: Romosozumab data show increased cardiovascular risk

May 22, 2017
Treatment with the anti-sclerostin monoclonal antibody romosozumab resulted in fewer new fractures in postmenopausal women with high-risk…

Meeting News

Recent trials advance lipidology knowledge base

May 21, 2017
PHILADELPHIA — Numerous important trials in clinical lipidology have been reported over the last year, according to a presentation at the…

Meeting News

Diagnosis of Fredrickson-Levy-Lees dyslipidemias inconsistent

May 21, 2017
PHILADELPHIA — A variance in the two qualitative approaches to diagnose patients with Fredrickson-Levy-Lees dyslipidemias may explain the…

Meeting News

FOURIER: Evolocumab reduces CV events regardless of baseline LDL, statin intensity

May 21, 2017
PHILADELPHIA — A subanalysis of the FOURIER trial presented at the National Lipid Association Scientific Sessions found that evolocumab was…

Meeting News

PCSK9 inhibition reduces LDL in patients on top of other therapies

May 21, 2017
PHILADELPHIA — In a real-world cohort of patients on maximally tolerated lipid-lowering therapies, PCSK9 inhibitors lowered LDL by 26% to 52%…

Meeting News

PCSK9 inhibitors recommended by NLA for certain patient groups

May 20, 2017
PHILADELPHIA — A National Lipid Association expert panel prepared updated recommendations for the use of PCSK9 antibody therapy at the NLA

More Headlines »
Advertisement
Advertisement